MADRID, Spain – An 11-month progression-free survival (PFS) benefit seen in the PACIFIC trial with Astrazeneca plc's PD-L1 inhibitor, Imfinzi (durvalumab), offers a new potential option for late-stage non-small-cell lung cancer (NSCLC) patients.
MADRID, Spain – Two phase III trials accepted as late-breaking abstracts for the European Society for Medical Oncology (ESMO) 2017 Congress showed abemaciclib reduced the risk of disease progression by 46 percent in advanced breast cancer and Cyramza (ramucirumab) improved progression-free survival (PFS) when added to docetaxel in advanced or metastatic urothelial cancer.
MADRID, Spain – Enthusiasm among oncologists Monday following positive results from two phase III late-stage melanoma trials – one for an immunotherapy, the other for a combination targeted therapy – suggested Opdivo (nivolumab) and Tafinlar (dabrafenib) may soon replace interferon in Europe and Yervoy (ipilimumab) in the U.S. at the adjuvant setting.
MADRID, Spain – The rapid approval of immunotherapies that began a decade ago has oncologists and researchers brainstorming ideas for patient benefit, all asking the same question: What's next?
A rising interest in the neurodegenerative (ND) disease space has sparked a flurry of high-money deals, with the last three years indicating a doubling in the number of collaborations and licensing agreements, plus an 87 percent incline in deal value, when compared to the previous three years.
SAN DIEGO – Nobody wants to get old. Health declines, disease increases and insurance costs skyrocket. But what if researchers could slow the process at the cellular level, reverting stem cells to their youthful state, or clearing senescent cells, a hallmark of advanced years?
SAN DIEGO – As scientists and business leaders discussed innovation, valuation, transformative therapies and coming epidemics in various rooms throughout the San Diego Convention Center, something different occurred in Room 5B on Wednesday afternoon during BIO's International Convention.
SAN DIEGO – Frustrations abound as scientists work feverishly for a curative Alzheimer's disease drug, and business leaders seek ways to fund the research. In the meantime, their parents and grandparents are stuck in the middle of failed or unproven treatments and a real fear that time is running out.
SAN DIEGO – Buzzing through the halls, amid private discussions and public panels, a technology that some say could dramatically transform therapeutic development teeters at the forefront of many BIO 2017 discussions.
